Abstract
The antinociception mediated by supraspinal opioid receptors has traditionally been thought to arise solely from activation of the μ-opioid receptor subtype. There is a growing body of evidence, however, which suggests that supraspinal δ-opioid receptors may also be able to directly initiate antinociception. Frank Porreca and colleagues review the evidence favoring exclusive involvement of μ-opioid receptors (as well as studies implicating δ-opioid receptors) in supraspinal antinociceptors. They conclude that δ-opioid receptors can be pharmacologically activated to initiate antinociception, suggesting the existence of an alternative mechanism for pain relief which may be of significant clinical importance.
Original language | English (US) |
---|---|
Pages (from-to) | 134-138 |
Number of pages | 5 |
Journal | Trends in Pharmacological Sciences |
Volume | 9 |
Issue number | 4 |
DOIs | |
State | Published - Apr 1988 |
Keywords
- (2s
- 3r)-(3-Amino-2-hydroxy-4-phenylbutanoyl)-l-Leucine
- Allyl-Tyr-Aib-Aib-Phe-Leu-OH
- Bestatin
- H-Tyr-d-Pen-Gly-Phe-Pen-OH(non-cyclic)
- ICI-154129
- ICI-174864
- LY-198572
- N
- N-bisallyl-Tyr-Gly-Gly-ψ-(CHS)-Phe-Leu-OH
- PLO17
- Thiorphan
- [N-Me-Phe
- d-Promorphiceptin
- dl-3-mercapto-2-benzylpro-panoyl-glycine
- where Pen is penicillamine
ASJC Scopus subject areas
- Toxicology
- Pharmacology